Inventor · disambiguated record
Andrew W. Buesking
Also filed as: BUESKING ANDREW · BUESKING ANDREW W
22 granted patents·10 pending applications·181 citations·filing 2014–2025
95Inventor score
Top patents by PatentIndex Score
32 records- 0197US10138248B2Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitorsINCYTE CORP·Filed 2017·Granted Nov 27, 2018·36 cites·24 claims
- 0297US9737516B2Bicyclic heterocycles as bet protein inhibitorsINCYTE CORP·Filed 2016·Granted Aug 22, 2017·25 cites·52 claims
- 0396US10472368B2Heterocyclic compounds as PI3K-γ inhibitorsINCYTE CORP·Filed 2018·Granted Nov 12, 2019·12 cites·28 claims
- 0496US9315501B2Bicyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2014·Granted Apr 19, 2016·33 cites·41 claims
- 0595US11225486B2Tertiary alcohols as PI3K-γ inhibitorsINCYTE CORP·Filed 2020·Granted Jan 18, 2022·4 cites·51 claims
- 0694US10022387B2Aza-heteroaryl compounds as PI3K-gamma inhibitorsINCYTE CORP·Filed 2017·Granted Jul 17, 2018·15 cites·35 claims
- 0793US11926630B2Tertiary alcohols as PI3K-γ inhibitorsINCYTE CORP·Filed 2021·Granted Mar 12, 2024·2 cites·2 claims
- 0893US10975088B2Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitorsINCYTE CORP·Filed 2019·Granted Apr 13, 2021·6 cites·13 claims
- 0993US10479795B2Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitorsINCYTE CORP·Filed 2018·Granted Nov 19, 2019·13 cites·45 claims
- 1093US9586949B2Aza-heteroaryl compounds as PI3K-gamma inhibitorsINCYTE CORP·Filed 2016·Granted Mar 7, 2017·14 cites·26 claims
- 1192US11767323B2Tricyclic pyridone compounds as JAK2 V617F inhibitorsINCYTE CORP·Filed 2021·Granted Sep 26, 2023·3 cites·37 claims
- 1290US11919908B2Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitorsINCYTE CORP·Filed 2021·Granted Mar 5, 2024·2 cites·42 claims
- 1390US11046658B2Aminopyrazine derivatives as PI3K-γ inhibitorsINCYTE CORP·Filed 2019·Granted Jun 29, 2021·4 cites·23 claims
- 1488US10738057B2Tertiary alcohols as PI3K-γ inhibitorsINCYTE CORP·Filed 2018·Granted Aug 11, 2020·5 cites·38 claims
- 1586US11091491B2Heterocyclic compounds as PI3K-y inhibitorsINCYTE CORP·Filed 2019·Granted Aug 17, 2021·4 cites·37 claims
- 1684US11352340B2Pyridine and pyridimine compounds as PI3K-gamma inhibitorsINCYTE CORP·Filed 2019·Granted Jun 7, 2022·3 cites·22 claims
- 1782US2025388553A1AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORSINCYTE CORP·Filed 2025·Application pending·0 cites
- 1875US12030885B2Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitorsINCYTE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·20 claims
- 1975US11773102B2Heterocyclic compounds as PI3K-γ inhibitorsINCYTE CORP·Filed 2021·Granted Oct 3, 2023·0 cites·27 claims
- 2074US11952367B2Pyridine and pyridimine compounds as PI3K-gamma inhibitorsINCYTE CORP·Filed 2022·Granted Apr 9, 2024·0 cites·29 claims
- 2171US2025163074A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2270US12421197B2Aminopyrazine derivatives as PI3K-γ inhibitorsINCYTE CORP·Filed 2021·Granted Sep 23, 2025·0 cites·28 claims
- 2367US2023357265A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2466US2025059175A1Mutant Pi3k-Alpha Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2564US2025161289A1KAT6 Targeting CompoundsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2663US12129262B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Oct 29, 2024·0 cites·29 claims
- 2763US11685744B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Jun 27, 2023·0 cites·54 claims
- 2859US2024124422A1Mutant pi3k-alpha inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2957US2023416240A1Kat6 targeting compoundsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3056US2025197418A1Polymorphic Compounds And Uses ThereofPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3152US2017190689A1Pyridine and pyridimine compounds as pi3k-gamma inhibitorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 3245US2025276074A1Brm and brg1 targeting antibody-drug conjugates and methods of use thereofPRELUDE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew W. Buesking files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →